(June 2015). Eluxadoline (INN, USAN) (brand name Viberzi; former developmental code name JNJ-27018966) is a novel, orally-active drug approved for the treatment of diarrhea and abdominal pain in individuals with diarrhea-predominant irritable bowel syndrome (IBS-D). Following a 100 mg dose of eluxadoline, the Cmax was about 2 to 4 ng/ml and AUC was 12-22 ng.h/ml. Eluxadoline has linear pharmacokinetics with no accumulation upon repeated twice daily dosing. Its plasma protein binding was 81% and its half life was 3.7 to 6 hours and it was excreted mainly in feces.